CannabisNewsBreaks

WednesdayAug 10, 2022 12:22 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Earnings Conference Call, Webcast

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has scheduled a conference call and webcast to discuss its earnings for the first half of 2022. The call is slated for Monday, Aug. 15, 2022, at 4:30 p.m. ET. the company plans to release its financial report and numbers prior to the call. During the call, company officials will discuss the financial and operations results as well as provide an update on the company’s operations, house of brands and life sciences strategies; the event will also include time for a Q&A. An…

Continue Reading

TuesdayAug 09, 2022 12:41 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

Continue Reading

MondayAug 08, 2022 12:48 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Poised in the ‘Future of Agriculture’

Advanced Container Technologies (OTC: ACTX) today announced that it is operating in a sector that Barclays Bank says is gaining traction as a sector for investment. According to Jed Lynch, head of Americas, sustainable and impact investment banking at Barclays, “Agriculture has historically been viewed as a mature industry, but we are now seeing significant technology-led innovation across the sector. As a result, we’re seeing a noticeable increase in high-growth startups, venture funding, M&A activity and public-market interest in this space.” “We are in the right sector at the right time,” Douglas Heldoorn, CEO of Advanced Container Technologies, said in…

Continue Reading

TuesdayAug 02, 2022 1:53 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) patented DehydraTECH(TM) has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. Studies have also demonstrated DehydraTECH’s ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances, with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery. “DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a…

Continue Reading

TuesdayAug 02, 2022 11:40 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters Joint Venture with Colombia’s Largest Indigenous Tribe

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced a joint venture agreement with Pharma Indigena Misak Manasr Sas (“Manasr”), the largest indigenous tribe in Colombia, on the development of cultivation best practices, manufacturing, export, and marketing of cannabis and cannabis containing products. “We are honored to be given opportunity to work hand-in-hand with the Misak people,” said Luis Merchan, Flora’s chairman and CEO. “Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform…

Continue Reading

WednesdayJul 27, 2022 1:32 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised with Strong In-Market Brand Portfolio, Cultivation and Export Capabilities

Flora Growth Corp. (NASDAQ: FLGC) recently reported that its board of directors had authorized the repurchase of up to $5 million of its outstanding common shares. “These recent developments highlight Flora management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment,” a recent article reads. “While making the announcement, Luis Merchan, Flora’s chairman and CEO, noted: ‘Flora continues to move assertively to execute…

Continue Reading

WednesdayJul 27, 2022 12:09 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this…

Continue Reading

TuesdayJul 26, 2022 1:27 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand “Ko.” According to the update, the brand was launched for the Japanese consumer market on July 21, 2022. Premier will create its own e-commerce infrastructure and digital marketing campaigns in collaboration with its parent company, Premier Anti-Aging Co. Ltd., which is listed on the Tokyo Stock Exchange (4934:JP). The Ko brand will contain CBD and other botanical extracts and is focused on…

Continue Reading

TuesdayJul 26, 2022 1:16 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Notes Reports Indicating Agriculture May Be ‘Recession-Proof’ Space

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, is pointing to a new study indicating that agriculture may be “one of the most recession proof sectors” because despite economic conditions, people still need food. The Money Made report studied the performance of 12 different asset classes against the S&P 500 during three recent market crashes, concluding that agriculture came out on top overall, averaging returns that are at least 24% better than those of the S&P 500. The company also noted that Small Business Trends News reported that the agriculture industry is one…

Continue Reading

MondayJul 25, 2022 11:56 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed…

Continue Reading